Integra LifeSciences (NASDAQ:IART) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Integra LifeSciences (NASDAQ:IART) posted its quarterly earnings data on Monday. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01, Briefing.com reports. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The company had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same quarter last year, the firm posted $0.71 earnings per share. The business’s quarterly revenue was up 9.7% on a year-over-year basis.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART traded down $0.28 during trading on Tuesday, reaching $25.14. 602,631 shares of the company’s stock traded hands, compared to its average volume of 1,119,833. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. The company has a 50 day moving average of $29.72 and a 200-day moving average of $33.65. Integra LifeSciences has a 12 month low of $22.36 and a 12 month high of $46.09. The stock has a market capitalization of $1.98 billion, a P/E ratio of 50.84, a price-to-earnings-growth ratio of 1.14 and a beta of 1.11.

Insider Buying and Selling at Integra LifeSciences

In related news, Chairman Stuart Essig purchased 52,641 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The shares were acquired at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the acquisition, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

IART has been the topic of a number of analyst reports. Bank of America dropped their target price on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a research report on Tuesday, May 7th. JMP Securities reduced their target price on Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research note on Tuesday, May 7th. BTIG Research cut shares of Integra LifeSciences from a “neutral” rating to a “sell” rating and set a $22.00 price target on the stock. in a report on Tuesday. StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Finally, Oppenheimer lowered shares of Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 7th. Four research analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences currently has a consensus rating of “Hold” and an average target price of $29.88.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.